2013 Statistics for Global Prescription Medications: CNS Therapeutics Maintain a Leading Position among Small Molecule Therapeutics
http://pubs.acs.org/....1021/cn500063v (full article, freely available)
With total 2013 annual sales of $23 Billion, it's easy to see why Lilly is freaked out about the $9 Billion loss on the MDL that was just entered. (See article I posted earlier this evening.) That's almost 1/2 of their annual total sales for last year.
Granted, that amount will likely be reduced somewhat by further legal proceedings, and will be apportioned with the co-defendant Takeda, but it's still going to be a huge kick in the butt.
Table 1. Top 20 Global Prescription Drugs in Terms of Sales in 2013
rank product sales(US $ Bn)
1 Humira 9.85
2 Seretide 9.21
3 Crestor 8.14
4 Enbrel 7.94
5 Lantus 7.93
6 Nexium 7.86
7 Abilify 7.83
8 Remicade 7.67
9 Cymbalta 6.46
10 MabThera 6.26
11 Avastin 5.71
12 Spiriva 5.31
13 Herceptin 5.17
14 Lyrica 5.12
15 Copaxone 4.69
16 Januvia 4.46
17 Lucentis 4.41
18 Neulasta 4.40
19 Glivec 4.13
20 Atripla 4.01
Table 3. Top 10 Global Pharmaceutical Corporations in 2013 in Terms of Sales(1)
rank company sales (US$Bn) 2013 growth (%)
1 Novartis 50.5 +1.9
2 Pfizer 44.3 –2.6
3 Sanofi-Aventis 38.1 +1.4
4 Merck & Co. 36.3 –7.0
5 Roche 36.1 +5.3
6 GlaxoSmithKline 32.5 +1.5
7 Johnson &Johnson 30.7 +12.2
8 AstraZeneca 30.2 –2.9
9 Teva 24.2 –1.8
10 Eli Lilly 23.0 +8.4